We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Training Therapists to Administer Contingency Management-Patient Phase - 3

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00249418
First Posted: November 7, 2005
Last Update Posted: November 21, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
UConn Health
  Purpose
The purpose of this study is to train therapists to administer contingency management (CM). This project will train up to 42 community-based treatment providers about the rationale for and the specifics of administering CM. Initial training will occur in 2-day workshops, followed by weekly supervision in delivery of CM with test cases. We expect that the majority of therapists will achieve high levels of competence and adherence in administering CM treatment within 3-5 test cases, as measured by ratings of audiotapes. To examine the efficacy of CM, each therapist who achieves adherence and competence in delivering CM will administer standard treatment alone or standard treatment plus CM to substance-abusing outpatients. In the CM condition, patients will have the opportunity to win prizes for submission of negative samples, and the treatment will be in effect for 12 weeks. In total, up to 200 patients will be randomly assigned to one of the two conditions. A research evaluator will conduct follow-up assessments, scheduled for 3, 6 and 9 months after treatment initiation.

Condition Intervention
Substance Abuse Behavioral: Contingency management

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Training Therapists to Administer Contingency Management-Patient Phase

Further study details as provided by UConn Health:

Primary Outcome Measures:
  • Drug use [ Time Frame: baseline and each follow-up ]
  • Retention [ Time Frame: each follow-up ]

Enrollment: 180
Study Start Date: January 2004
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Contingency management
    Rewards (prizes) for abstinence
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • age 18 years or older
  • meets DSM-IV criteria for cocaine abuse or dependence
  • English speaking (est. >90% of patients)

For those in drug-free programs, they must have initiated treatment within the past week. For methadone patients, they must be stabilized on a dose of methadone, defined as being on the same dose for at least 30 days and not currently requesting or being considered for a dose modification. Methadone patients must also have submitted at least 30% cocaine positive urine samples in the past 3 months.

Exclusion criteria:

  • acute uncontrolled psychiatric disorder (psychosis, suicidality) as determined by the SCID
  • dementia (<23 on the Mini Mental State Exam; Folstein & Folstein, 1975)
  • in recovery for pathological gambling
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00249418


Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Nancy Petry, Ph.D. UConn Health
  More Information

Responsible Party: UConn Health
ClinicalTrials.gov Identifier: NCT00249418     History of Changes
Other Study ID Numbers: NIDA-16855-3
R01DA016855 ( U.S. NIH Grant/Contract )
First Submitted: November 3, 2005
First Posted: November 7, 2005
Last Update Posted: November 21, 2011
Last Verified: November 2011

Keywords provided by UConn Health:
Contingency Management
Substance Abuse Treatment

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders